Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CoVepiT Vaccine Phase 1 Study in Healthy Adults
NCT04885361Phase 1Unknown
- Sponsor
- OSE Immunotherapeutics
- Start
- May 2021
- Primary completion
- Sep 2021
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CoVepiT in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by OSE Immunotherapeutics. Primary endpoints: Incidence of solicited local reactogenicity signs and symptoms, Incidence of solicited systemic reactogenicity signs and symptoms and 4 more. Status: unknown.
02
Drugs
CoVepiT
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04885361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04885361.